As investor sentiment shifts from a ‘risk-on’ appetite for high-growth technology stocks to a more cautious ‘risk-off’ stance, a discernible rotation into stable, income-generating assets is underway. This strategic pivot, observed as of May 22, 2026, is leading many to re-evaluate their portfolios, seeking resilience and consistent returns outside the often-volatile tech sector. For those looking to reallocate capital, particularly a $10,000 investment, three dividend-growth stocks stand out as compelling options: pharmaceutical giant AbbVie, consumer staples behemoth Procter & Gamble, and energy infrastructure leader Enterprise Products Partners.
The Shifting Tides of Investment
Historically, periods of investor exuberance often see capital flow into growth-oriented technology stocks, driven by the promise of rapid expansion and disruptive innovation. However, when market conditions become more uncertain, or a ‘risk-off mood’ prevails, investors frequently recalibrate, moving away from speculative growth and towards established businesses with predictable cash flows and a history of shareholder returns. High-yielding dividend growth stocks, in particular, tend to attract increased interest during such rotations, offering a blend of income and potential capital appreciation from fundamentally sound enterprises.
AbbVie: A Pharmaceutical Powerhouse with a Royal Dividend
Pharmaceutical giant AbbVie (NYSE: ABBV) presents a robust case for investors seeking stability and income. Recognized as a ‘Dividend King,’ the company boasts an impressive record of over five decades of annual dividend increases. This lineage is traced back to its spin-off from Abbott (NYSE: ABT), retaining Abbott’s extensive dividend history. Currently, AbbVie offers an attractive 3.2% dividend yield, significantly outperforming the S&P 500’s approximate 1.1% yield and the average pharma stock’s 0.7% yield, as noted in the source article.
While concerns have lingered regarding generic competition for its blockbuster drug Humira, AbbVie’s future appears well-fortified by its next-generation immunology drugs, Skyrizi and Rinvoq. These new treatments are reportedly even more effective, signaling strong potential for continued revenue growth. Beyond immunology, AbbVie maintains strong positions in oncology, neuroscience, and aesthetics, diversifying its revenue streams. For an investor considering a $10,000 allocation, this would translate to approximately 45 shares of AbbVie, offering a blend of defensive strength and consistent income.
Procter & Gamble: Consumer Staples Stability
Another ‘Dividend King’ drawing attention in the current market environment is Procter & Gamble (NYSE: PG), one of the world’s largest consumer staples companies. P&G’s business model is inherently defensive; its products, ranging from toilet paper to deodorant and dish soap, are considered necessities that consumers continue to purchase regardless of economic conditions or stock market fluctuations. The company’s unwavering focus on innovation and product superiority has fostered deep brand loyalty, underpinning its consistent performance.
Despite its industry-leading position, which often commands a premium on Wall Street, P&G has recently experienced a drawdown. This has pushed its price-to-sales, price-to-earnings, and price-to-book ratios below their five-year averages, suggesting an attractive entry point for investors. The company’s 3% dividend yield also stands notably above the industry average of 2%. A $10,000 investment in P&G would allow an investor to acquire around 70 shares, securing exposure to a resilient business with a proven track record of returning capital to shareholders.
Enterprise Products Partners: High Yield from Energy Infrastructure
While not yet a ‘Dividend King,’ Enterprise Products Partners (NYSE: EPD) presents a compelling high-yield opportunity for investors rotating out of tech. This energy business has consistently increased its distribution annually for 27 consecutive years, a streak that effectively covers every year since its initial public offering. This remarkable consistency underscores its reliability as an income-generating asset.
Enterprise operates as a ‘boring toll-taker’ in the energy sector, generating fees from its vast portfolio of North American energy infrastructure assets, primarily pipelines. The company’s revenue is more dependent on the volume of energy flowing through its system than on the fluctuating price of energy commodities. Given the indispensable role of oil and natural gas in the global economy, demand for Enterprise’s services tends to remain robust across various energy cycles. The primary allure for income-focused investors is its ultra-high 5.5% distribution yield. As a master limited partnership (MLP), Enterprise maintains an investment-grade credit rating and boasts a strong distribution coverage ratio of 1.7x with distributable cash flow, mitigating concerns about potential cuts. Instead, continued slow-and-steady distribution growth is anticipated. A $10,000 investment would secure approximately 250 units of EPD, providing substantial income generation.
For investors navigating a market rotation away from technology’s inherent volatility, leaning into established businesses with robust dividend growth histories offers a strategic pathway to reduce risk while maintaining exposure to growth. AbbVie, Procter & Gamble, and Enterprise Products Partners exemplify this approach, providing strong businesses, attractive yields, and long records of rewarding shareholders with growing income streams, making them compelling considerations for long-term portfolio stability.
